Losardil25 mg+12.5 mg

Losardil 25 mg+12.5 mg is a fixed-dose combination antihypertensive used in the following situations:

Established/FDA-approved uses

• Hypertension requiring combination therapy: Treatment of high blood pressure in adult patients who are not adequately controlled on either losartan or hydrochlorothiazide alone, or as initial therapy in patients likely to need multiple drugs to reach their blood pressure goal.
• Risk reduction of stroke: In hypertensive patients with left ventricular hypertrophy (an enlarged heart muscle), Losardil 25 mg+12.5 mg-containing regimens (starting with losartan) reduce the risk of stroke; this specific benefit has not been shown in Black patients.

Losardil 25 mg+12.5 mg is not intended as first-line initial therapy for patients whose blood pressure can be controlled by a single agent; it is reserved for patients needing combination treatment.

Each tablet of Losardil 25 mg+12.5 mg contains two active ingredients:

• Losartan potassium - an angiotensin II receptor blocker (ARB), available in strengths such as 25 mg, 50 mg, or 100 mg.
• Hydrochlorothiazide - a thiazide-type diuretic, available in strengths such as 12.5 mg or 25 mg.

Common marketed tablet combinations include 50 mg/12.5 mg and 100 mg/25 mg, along with other locally available strengths.

Losardil 25 mg+12.5 mg is a combination medicine that brings together two complementary mechanisms to lower blood pressure. Losartan blocks the action of angiotensin II, a hormone that narrows blood vessels and promotes salt and water retention, while hydrochlorothiazide is a diuretic ('water pill') that helps the kidneys remove excess salt and water from the body. Together, these two components produce a greater blood-pressure-lowering effect than either drug alone, and are used specifically for patients whose hypertension needs more than a single medicine to control.

Losardil 25 mg+12.5 mg belongs to the therapeutic class of combination antihypertensives, specifically an Angiotensin II Receptor Blocker (ARB) combined with a thiazide diuretic.

Losardil 25 mg+12.5 mg combines two distinct but complementary mechanisms of blood pressure control:

• Losartan selectively blocks the AT1 receptor, preventing angiotensin II from causing vasoconstriction and from stimulating aldosterone release. This lowers blood pressure and reduces the tendency toward potassium loss caused by aldosterone.
• Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal renal tubule, increasing excretion of sodium, chloride, and water, which reduces circulating blood volume and blood pressure. It also tends to increase potassium and uric acid excretion (potassium loss) and can raise blood glucose and calcium levels.

The combination in Losardil 25 mg+12.5 mg produces an additive antihypertensive effect, and the opposing effects of the two components on potassium levels tend to offset each other, though net electrolyte status still requires monitoring. The antihypertensive effect is generally seen within 1-2 weeks, with a fuller effect by about 3 weeks.

Take Losardil 25 mg+12.5 mg orally, once daily, with or without food, swallowed whole with water. Try to take it at the same time each day to maintain consistent blood pressure control.

Losardil 25 mg+12.5 mg has several clinically significant drug interactions:

• Potassium supplements, potassium-sparing diuretics, or salt substitutes containing potassium: may increase the risk of hyperkalemia (high blood potassium) due to the losartan component; combined use requires caution and monitoring.
• Other drugs that affect the renin-angiotensin system (ACE inhibitors, aliskiren, other ARBs): increase the risk of hypotension, hyperkalemia, and changes in kidney function; concurrent use of aliskiren is contraindicated in patients with diabetes.
• Lithium: both ARBs and thiazide diuretics reduce lithium clearance, increasing the risk of lithium toxicity; concurrent use is generally not recommended, and lithium levels should be monitored closely if unavoidable.
• NSAIDs (e.g., ibuprofen, indomethacin): may reduce the antihypertensive effect and increase the risk of kidney impairment, particularly in patients who are elderly, volume-depleted, or have pre-existing renal disease.
• Other antihypertensive drugs and alcohol: may cause additive blood-pressure-lowering effects, increasing the risk of symptomatic hypotension.
• Antidiabetic drugs (insulin, oral hypoglycemics): the hydrochlorothiazide component can raise blood glucose, sometimes requiring dose adjustment of antidiabetic therapy.
• Corticosteroids, ACTH, or other drugs causing potassium loss: may increase the risk of hypokalemia when combined with the diuretic component.

Always inform the physician or pharmacist of all medicines, supplements, and herbal products being used before starting Losardil 25 mg+12.5 mg.

Most patients tolerate Losardil 25 mg+12.5 mg well. Reported side effects include:

Common

• Dizziness or lightheadedness
• Upper respiratory tract infection symptoms
• Cough
• Back pain
• Fatigue

Less common but clinically important

• Electrolyte disturbances - hyperkalemia, hyponatremia, or hypokalemia (see Precautions and Warnings)
• Increased blood uric acid levels or gout flare
• Increased blood glucose
• Photosensitivity (increased sun sensitivity/skin reaction)
• Changes in kidney function tests

Rare but serious

• Angioedema (swelling of the face, lips, tongue, or throat) - seek emergency care immediately if this occurs
• Significant drop in blood pressure, particularly after the first dose in volume-depleted patients
• Severe skin reactions

Patients should report any unusual or persistent symptoms to their physician.

Pregnancy: Losardil 25 mg+12.5 mg is contraindicated in pregnancy. Drugs that act on the renin-angiotensin system, including the losartan component, can cause fetal injury and death when used during the second and third trimesters. If pregnancy is detected, Losardil 25 mg+12.5 mg should be discontinued as soon as possible and the physician informed so that alternative therapy can be arranged.

Lactation: It is not well established whether the components of Losardil 25 mg+12.5 mg pass into breast milk in clinically significant amounts. Thiazide diuretics are known to be excreted in breast milk and may suppress lactation. Because of the potential for serious adverse effects in a nursing infant, a decision should be made whether to discontinue breastfeeding or discontinue the drug, taking into account the importance of the medicine to the mother - only under medical supervision.

The following precautions apply to Losardil 25 mg+12.5 mg:

• Hypotension: Symptomatic low blood pressure may occur, especially in volume- or salt-depleted patients (e.g., those on high-dose diuretics); correct volume depletion before starting therapy where possible.
• Electrolyte disturbances: The combination can cause hyperkalemia (more likely with renal impairment, diabetes, or concurrent potassium-sparing agents) as well as hypokalemia, hyponatremia, hypomagnesemia, hypercalcemia, and hyperuricemia (which may precipitate gout). Periodic monitoring of serum electrolytes is recommended.
• Renal function: May alter kidney function, particularly in patients with renal artery stenosis, pre-existing kidney disease, heart failure, or volume depletion; renal function should be monitored periodically.
• Hepatic impairment: Use with caution; thiazides and ARBs are cleared partly through hepatic pathways, and minor fluid/electrolyte changes can precipitate hepatic coma in susceptible patients.
• Metabolic effects: May raise blood glucose and cholesterol/triglyceride levels; monitor in patients with diabetes or dyslipidemia.
• Photosensitivity: The hydrochlorothiazide component may increase sensitivity to sunlight; advise patients to use sun protection.
• Angioedema: Rare but potentially life-threatening; discontinue immediately and seek emergency care if swelling of the face, lips, tongue, or airway occurs.
• Sulfonamide allergy: Patients with a history of allergy to sulfonamide-derived drugs may have cross-sensitivity to the hydrochlorothiazide component.

Overdose with Losardil 25 mg+12.5 mg may cause marked hypotension, dizziness, fast or slow heart rate, and signs of electrolyte imbalance or dehydration (such as excessive urination, muscle cramps, or confusion) from the diuretic component.

If an overdose is suspected, seek immediate medical attention or contact emergency services/a poison control center right away. Treatment is supportive and should be provided under medical supervision (such as monitoring vital signs and correcting fluid/electrolyte imbalance); Losardil 25 mg+12.5 mg should not be treated with home remedies, and patients should not attempt to manage a suspected overdose without professional medical care. Losartan is not effectively removed by hemodialysis.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly

No overall dosage adjustment is generally required based on age alone, but elderly patients may be more sensitive to blood-pressure-lowering and electrolyte effects; monitor closely.

Renal impairment

Standard doses may be used with mild-to-moderate renal impairment. Safety has not been established in severe renal impairment (very low kidney function), and thiazide diuretics tend to become less effective as kidney function declines further.

Hepatic impairment

Losardil 25 mg+12.5 mg is not recommended to initiate therapy in patients with hepatic impairment because an appropriately reduced starting dose is not available in this fixed-dose combination.

Pediatric patients

Safety and efficacy of Losardil 25 mg+12.5 mg have not been established in pediatric patients; it is not recommended for use in children.

Black patients

The stroke-risk-reduction benefit seen with losartan-based regimens in hypertensive patients with left ventricular hypertrophy has not been demonstrated in Black patients; alternative therapy may be considered for this specific benefit.

Duration of treatment with Losardil 25 mg+12.5 mg is determined by the physician and is typically long-term/ongoing, since hypertension usually requires continuous management. Blood pressure response is usually evident within 1-2 weeks, with the fuller effect seen by about 3 weeks. Treatment should not be stopped abruptly without medical advice, even if blood pressure appears well controlled.

Angiotensin II Receptor Blocker (ARB) + Thiazide diuretic (combination antihypertensive).

Losardil 25 mg+12.5 mg works through two complementary mechanisms. The losartan component selectively blocks the AT1 angiotensin II receptor, preventing angiotensin II-mediated vasoconstriction and aldosterone secretion, which relaxes blood vessels and lowers blood pressure while limiting potassium loss. The hydrochlorothiazide component inhibits sodium and chloride reabsorption at the distal convoluted tubule of the kidney, promoting excretion of sodium and water, which reduces plasma and extracellular fluid volume and lowers blood pressure. Together, the two mechanisms produce a greater antihypertensive effect than either component alone.

The safety and efficacy of Losardil 25 mg+12.5 mg have not been established in pediatric patients (children and adolescents). It is therefore not recommended for use in this population, and alternative antihypertensive strategies appropriate for children should be discussed with a pediatrician.